Dear Sir/Madam,

Prostate Cancer UK was delighted to learn that NICE are proposing to recommend the use of enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen. We believe that the Committee has taken account of the criteria as set out in the Appraisal consultation document.

We hope this decision is confirmed at the Committee meeting on 20th November 2013. We would then urge the Final Appraisal Document be published as soon as possible.

Yours sincerely,

[redacted]

[redacted]
Senior Policy Officer
Prostate Cancer UK

The Counting House
53 Tooley Street
London
SE1 2QN
T: [redacted]
E: [redacted]